Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: Embodiments described include systems and methods for displaying overlays for a network application. A client application on a client device can establish a session to a network application accessed via an embedded browser of the client application. The embedded browser of the client application may receive and display a web page of the network application. Based on one or more conditions and/or policies, the client application may identify and display overlay content over the web page in the embedded browser. The overlay content may include, but is not limited to, training videos, tutorials, social options (e.g., emoticons, likes), form help text, form autofill suggestions, and/or navigation assistance. Once the overlay content is presented, feedback can be received in order to modify the subsequent overlays.

Abstract: Described embodiments provide systems, methods, non-transitory computer-readable medium for using a single sign-on (SSO) to access an application. A client application on a client device in communication with an identity provider and an application on a remote computing device. The client application can authenticate a user via an identity provider to establish an authentication session. The client application can identify a request to access a uniform resource locator (URL) of the application hosted on the remote computing device. The client application can determine that a configuration of the client application identifies a remapped URL for the URL is available. The client application can access the remapped URL instead of the URL to cause the user to use the authentication session of the identity provider and be redirected from the identity provider to a link of the application on the remote computing device.

Abstract: A combustor for a gas turbine engine, the gas turbine engine defining a longitudinal centerline extending in a longitudinal direction, a radial direction extending orthogonally outward from the longitudinal centerline, and a circumferential direction extending concentrically around the longitudinal centerline, the combustor including: a liner at least partially defining a combustion chamber, the liner further defining a gap; and an intermediate member disposed at least partially within the gap of the liner and in fluid communication with the combustion chamber, wherein the intermediate member is retained at a relatively fixed position with respect to the liner by a support extending between the intermediate member and a case of the gas turbine engine.

Abstract: A combustor for a gas turbine engine, the gas turbine engine defining a longitudinal centerline extending in a longitudinal direction, a radial direction extending orthogonally outward from the longitudinal centerline, and a circumferential direction extending concentrically around the longitudinal centerline, the combustor including: a liner at least partially defining a combustion chamber, the liner including a dilution slot in fluid communication with the combustion chamber; and one or more guides configured to redirect cooling medium into the dilution slot.

Abstract: A combustor for a gas turbine engine, the gas turbine engine defining a longitudinal centerline extending in a longitudinal direction, a radial direction extending orthogonally outward from the longitudinal centerline, and a circumferential direction extending concentrically around the longitudinal centerline, the combustor including: a forward liner segment; an aft liner segment disposed downstream from the forward liner segment relative to a direction of flow through the combustor, the forward and aft liner segments at least partially defining a combustion chamber; and an intermediate member disposed at least partially between the forward and aft liner segments and extending in the circumferential direction.

Abstract: A combustor for a gas turbine engine, the gas turbine engine defining a longitudinal centerline extending in a longitudinal direction, a radial direction extending orthogonally outward from the longitudinal centerline, and a circumferential direction extending concentrically around the longitudinal centerline, the combustor including: a forward liner segment; and an aft liner segment disposed downstream from the forward liner segment relative to a direction of flow through the combustor, the forward and aft liner segments at least partially defining a combustion chamber, wherein the forward and aft liner segments are coupled together at a moveable interface.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: A system for maintaining a state of a session of a network application across different client device is disclosed. A first client application establishes sessions of a user to a network application. Each of the sessions is accessed via a first embedded browser of a first client application. The first client application stores a state of the sessions to a workspace service in association with the user, and a context of the user to a workspace hub. A second client application establishes the sessions to the network application based on the state of the sessions obtained via the workspace service that are each accessed via a second embedded browser of the second client application. The second client application updates the state of the sessions to a second state based on detection of a state change and a context of the user obtained from the workspace hub.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: Embodiments described include systems and methods for delivering a network application. An intermediary device between a client device and a server hosting a network application establishes a connection with the network application. The intermediary device receives encoded application data and decodes the encoded application data. The application data is encoded graphics data or audio data. The decoded application data is renderable at the client device. The intermediary device transmits the decoded application graphics and/or audio data to a client application of the client application for rendering to provide user access to the network application.

Abstract: Embodiments described include systems and methods of determining one or more links of one or more network applications to access to perform a task is provided. The method can include receiving, by a server, a request from a client application on a client device. The request can identify a name of a task to be performed. The client application can include an embedded browser for accessing one or more network applications. The method can include determining, by the server, one or more links of the one or more network applications hosted on one or more third party servers that are to be used to perform a task identified by the name of the task. The method can include causing, responsive to the request and to perform the task, the embedded browser of the client application on the client device to access the one or more links of the one or more network applications hosted on the one or more third party servers.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.